Polycystic Ovarian Syndrome Treatment Global Market Report 2024

The polycystic ovarian syndrome treatment market size has grown strongly in recent years. It will grow from $4.49 billion in 2023 to $4.74 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth observed during the historical period can be attributed to heightened awareness, advancements in medical technology, shifts in lifestyle, innovations in the pharmaceutical industry, and government initiatives.

The polycystic ovarian syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $6.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The projected growth in the forecast period can be linked to personalized medicine, the adoption of telemedicine and remote monitoring, increased investments in research and development, a growing prevalence of healthcare needs, and a favorable regulatory environment. Prominent trends in this forecast period encompass a holistic approach to healthcare, patient-centered care models, the integration of digital health solutions, the implementation of multidisciplinary care teams, and a heightened focus on patient education.

The global increase in genetic and hormonal disorders is a significant driver behind the expansion of the polycystic ovarian syndrome (PCOS) treatment market. PCOS, a common hormonal disorder affecting premenopausal women worldwide, is characterized by reproductive, endocrine, and metabolic abnormalities. Its prevalence varies widely, ranging from 2.2% to 26% globally. For instance, in China, it varies from 2% to 7.5%, while in Sri Lanka, it stands at 6.3%. In South India, it's 9.13%, and in Maharashtra, it's as high as 22.5%. The increasing incidence of genetic and hormonal disorders globally is expected to drive the growth of the market for polycystic ovarian syndrome treatment.

The primary categories of drugs used in the treatment of polycystic ovarian syndrome include oral contraceptives, ornithine decarboxylase inhibitors, insulin-sensitizing agents, anti-depressants, diuretics, and aromatase inhibitors. Oral contraceptives are hormone-based medications taken orally to prevent pregnancy. They work by inhibiting ovulation and preventing sperm from reaching the cervix. Various surgical procedures, such as ovarian wedge resection and laparoscopic ovarian drilling, are performed in medical facilities, including hospitals, clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, and feminist health centers.

The polycystic ovarian syndrome treatment market research report is one of a series of new reports that provides polycystic ovarian syndrome treatment market statistics, including polycystic ovarian syndrome treatment industry global market size, regional shares, competitors with a polycystic ovarian syndrome treatment market share, detailed polycystic ovarian syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the polycystic ovarian syndrome treatment industry. This polycystic ovarian syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The surge in lifestyle and dietary changes is anticipated to propel the growth of the polycystic ovarian syndrome treatment market. Lifestyle and dietary changes involve modifying daily routines and eating habits, which can significantly impact the management and treatment of PCOS. These changes are often employed as primary or complementary approaches to alleviate symptoms and enhance the overall well-being of individuals with PCOS. For example, a McKinsey & Company article from October 2022 highlights the importance of healthy eating, with at least 70% of survey respondents in various countries expressing a desire to be healthy. Healthy eating is a priority for around half of consumers across all age groups. Hence, the increase in lifestyle and dietary changes is fostering the growth of the polycystic ovarian syndrome treatment market.

A significant impediment to the growth of the polycystic ovarian syndrome treatment market is the lack of drugs approved by regulatory bodies, including the FDA (Food and Drug Administration), in many countries. In the USA, for instance, the FDA has not approved pharmacological treatments for use in adolescents with PCOS. Although some pharmacological interventions are employed to manage PCOS symptoms, certain drugs like rimonabant, an appetite suppressant cannabinoid CB1 receptor antagonist, failed to gain FDA approval due to concerns about suicidal ideation and drug overdoses. Notably, Minoxidil is the only FDA-approved drug for treating female pattern baldness. Consequently, the absence of regulatory approvals in many countries is a key factor constraining the growth of the polycystic ovarian syndrome treatment market.

Laparoscopic ovarian drilling stands out as a significant trend fueling the growth of the polycystic ovarian syndrome treatment market. This surgical procedure is performed in critical cases to induce ovulation in women with PCOS. It is commonly used when women with PCOS struggle to ovulate, even after attempting weight loss and using fertility drugs. Research published in a 2021 study revealed varying efficacy results for ovarian drilling, with ovulation rates ranging from 30% to 90% and pregnancy rates from 13% to 80%.

Major companies operating in the polycystic ovarian syndrome treatment market are introducing innovative programs like the PCOS Drug Program to enhance their market presence. The PCOS Drug Program is a treatment plan that combines lifestyle modifications and medications to manage PCOS symptoms. For example, in April 2023, Celmatix Inc., a US-based biotech company, launched the PCOS Drug Program with the primary goal of improving ovarian function by addressing the root cause of PCOS symptoms. The program's latest medication initiative focuses on developing the first-ever oral FSH receptor.

In December 2021, Organon & Co., a US-based pharmaceutical company dedicated to women's health, acquired Forendo Pharma for $954 million. This strategic acquisition is part of Organon's commitment to advancing women's health and developing improved treatments. Forendo Pharma, a Finland-based clinical-stage pharmaceutical company, specializes in the areas of intracrinology and polycystic ovarian syndrome (PCOS).

Major companies operating in the polycystic ovarian syndrome treatment market include Bristol-Myer Squibb Co, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi SA, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott Laboratories, Addex Therapeutics Ltd., BIOCAD, Allergan plc., Johnson and Johnson, Ferring Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Organon & Co, Forendo Pharma Ltd., GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Mylan NV, Lupin Pharmaceuticals Inc., HRA Pharma SAS, CooperSurgical Inc., TherapeuticsMD Inc., Agile Therapeutics Inc., OvaScience Inc., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Glenmark Pharmaceuticals Limited

North America was the largest region in the polycystic ovarian syndrome treatment market in 2023. Western Europe was the second largest region in the polycystic ovarian syndrome treatment market. The regions covered in the polycystic ovarian syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the polycystic ovarian syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The polycystic ovarian syndrome treatment market includes revenue earned by first line drugs for treating hirustism, first line drugs for ovulation, and insulin sensitizing drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.